Combined with the results of network pharmacology, these discoveries indicate that FHD exerts the therapeutic effect on NS by targeting PTGS2, MAPK1, IL-6, and PI3K-Akt pathway. Here, PTGS2 is linked to hypoalphalipoproteinemia, primary, 1.